董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Guido J. Neels | 男 | Director | 70 | 14.22万美元 | 3.61 | 2019-07-08 |
| Thomas C. Wilder, III | 男 | Director | 55 | 13.41万美元 | 0.49 | 2019-07-08 |
| Daniel Lemaitre | 男 | Director and Chairman | 65 | 39.66万美元 | 2.40 | 2019-07-08 |
| John Onopchenko | 男 | Director and Chief Executive Officer | 61 | 219.82万美元 | 5.84 | 2019-07-08 |
| Guido J. Neels | 男 | Director | 70 | 未披露 | 未持股 | 2019-07-08 |
| Leslie V. Norwalk | 女 | Director | 53 | 13.55万美元 | 0.44 | 2019-07-08 |
| Gregory D. Waller | 男 | Director | 69 | 14.85万美元 | 0.51 | 2019-07-08 |
| Thomas F. Zenty, III | 男 | Director | 64 | 13.14万美元 | 1.00 | 2019-07-08 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Vaseem Mahboob | 男 | Chief Financial Officer | 50 | 150.03万美元 | 5.50 | 2019-07-08 |
| Jeremy Hayden | 男 | General Counsel and Corporate Secretary | 49 | 103.38万美元 | 1.13 | 2019-07-08 |
| Matthew Thompson | 男 | Chief Medical Officer | 57 | 149.85万美元 | 1.51 | 2019-07-08 |
| John Onopchenko | 男 | Director and Chief Executive Officer | 61 | 219.82万美元 | 5.84 | 2019-07-08 |
董事简历
中英对照 | 中文 | 英文- Guido J. Neels
-
Guido J. Neels自2015年8月起担任Axogen, Inc.的董事会成员。他一直担任EW Healthcare Partners L.P.的运营合伙人《娱乐周刊》自2013年2月开播。Neels先生于2006年8月加入EW担任合伙人，2008年晋升为董事总经理，直到被任命为运营合伙人。从2004年5月到2005年11月退休Neels先生担任首席运营官Guidant公司（“Guidant”），一个世界领导人在心血管医疗产品的发展，在那里他负责Guidant全球业务的四个操作单位——心脏节律管理、血管介入、心脏手术，和血管内的解决方案。从2002年12月到2004年5月，他担任Guidant总裁办公室的集团主席，负责全球销售运营、企业沟通、企业营销、投资者关系和政府关系。从2000年1月到2002年12月，他担任Guidant欧洲、中东、非洲和加拿大的总裁。Neels先生此前曾担任血管干预全球营销副总裁，以及德国和中欧业务的董事总经理。从1982年到1994年，直到Guidant从Eli Lilly和Co.分离出来成为一个独立的上市公司，他在美国和欧洲的Eli Lilly担任综合管理、销售和营销职位。从1972年到1980年，他在比利时和美国的Raychem Corporation担任信息技术、金融和制造职位。Neels先生目前任职于EW的某些投资组合公司的董事会，包括Entellus Medical, Endologix和Bioventus。此外，他还担任非营利组织Christel House International和Amici lovaniens的董事会成员，并担任丹麦Novo Holdings的顾问。他持有斯坦福大学（Stanford University）的工商管理硕士学位和比利时鲁汶大学（University of Leuven）的商业工程学位。
Guido J. Neels,has served as a member of Axogen, Inc. Board of Directors since August 2015. He has been an operating partner of EW Healthcare Partners L.P. ("EW") since February 2013. Mr. Neels joined EW as a Partner in August 2006, was promoted to Managing Director in 2008 and served in that position until being appointed to Operating Partner. From May 2004 through his retirement in November 2005, Mr. Neels served as Chief Operating Officer of Guidant Corporation ("Guidant"), a world leader in the development of cardiovascular medical products, where he was responsible for the global operations of Guidant's four operating units – Cardiac Rhythm Management,Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 through May 2004, Mr. Neels was Group Chairman, Office of the President at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 through December 2002, Mr. Neels was President of Guidant for Europe, Middle East, Africa and Canada. Mr. Neels previously served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. From 1982 through 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co. (NYSE: LLY), Mr. Neels held general management, sales and marketing positions at Eli Lilly in the United States and Europe. From 1972 through 1980, he held positions in information technology, finance and manufacturing at Raychem Corporation in Belgium and the United States. Mr. Neels currently serves on the board of directors of Bioventus LLC, a portfolio company of Essex Woodlands. In addition, Mr. Neels also serves on the board of directors for Christel House International and Amici Lovanienses, both not-for-profit organizations. Mr. Neels holds an M.B.A. from Stanford University and a business engineering degree from the University of Leuven in Belgium. - Guido J. Neels自2015年8月起担任Axogen, Inc.的董事会成员。他一直担任EW Healthcare Partners L.P.的运营合伙人《娱乐周刊》自2013年2月开播。Neels先生于2006年8月加入EW担任合伙人，2008年晋升为董事总经理，直到被任命为运营合伙人。从2004年5月到2005年11月退休Neels先生担任首席运营官Guidant公司（“Guidant”），一个世界领导人在心血管医疗产品的发展，在那里他负责Guidant全球业务的四个操作单位——心脏节律管理、血管介入、心脏手术，和血管内的解决方案。从2002年12月到2004年5月，他担任Guidant总裁办公室的集团主席，负责全球销售运营、企业沟通、企业营销、投资者关系和政府关系。从2000年1月到2002年12月，他担任Guidant欧洲、中东、非洲和加拿大的总裁。Neels先生此前曾担任血管干预全球营销副总裁，以及德国和中欧业务的董事总经理。从1982年到1994年，直到Guidant从Eli Lilly和Co.分离出来成为一个独立的上市公司，他在美国和欧洲的Eli Lilly担任综合管理、销售和营销职位。从1972年到1980年，他在比利时和美国的Raychem Corporation担任信息技术、金融和制造职位。Neels先生目前任职于EW的某些投资组合公司的董事会，包括Entellus Medical, Endologix和Bioventus。此外，他还担任非营利组织Christel House International和Amici lovaniens的董事会成员，并担任丹麦Novo Holdings的顾问。他持有斯坦福大学（Stanford University）的工商管理硕士学位和比利时鲁汶大学（University of Leuven）的商业工程学位。
- Guido J. Neels,has served as a member of Axogen, Inc. Board of Directors since August 2015. He has been an operating partner of EW Healthcare Partners L.P. ("EW") since February 2013. Mr. Neels joined EW as a Partner in August 2006, was promoted to Managing Director in 2008 and served in that position until being appointed to Operating Partner. From May 2004 through his retirement in November 2005, Mr. Neels served as Chief Operating Officer of Guidant Corporation ("Guidant"), a world leader in the development of cardiovascular medical products, where he was responsible for the global operations of Guidant's four operating units – Cardiac Rhythm Management,Vascular Intervention, Cardiac Surgery, and Endovascular Solutions. From December 2002 through May 2004, Mr. Neels was Group Chairman, Office of the President at Guidant, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. From January 2000 through December 2002, Mr. Neels was President of Guidant for Europe, Middle East, Africa and Canada. Mr. Neels previously served as Vice President of Global Marketing for Vascular Intervention and as Managing Director for German and Central European operations. From 1982 through 1994, until Guidant was spun off as an independent public company from Eli Lilly and Co. (NYSE: LLY), Mr. Neels held general management, sales and marketing positions at Eli Lilly in the United States and Europe. From 1972 through 1980, he held positions in information technology, finance and manufacturing at Raychem Corporation in Belgium and the United States. Mr. Neels currently serves on the board of directors of Bioventus LLC, a portfolio company of Essex Woodlands. In addition, Mr. Neels also serves on the board of directors for Christel House International and Amici Lovanienses, both not-for-profit organizations. Mr. Neels holds an M.B.A. from Stanford University and a business engineering degree from the University of Leuven in Belgium.
- Thomas C. Wilder, III
-
Thomas C. Wilder, III自2010年5月起担任董事会成员。自2010年2月起担任Sequent Medical, Inc.（一家私人持有的医疗器械公司，致力于开发用于治疗神经血管性疾病的创新设备）的总裁兼首席执行官。同时，担任Benvenue Medical（一家私人拥有的医疗设备公司，专注于为快速增长的微创脊柱外科市场设计、制造和销售尖端产品）的董事。从2009年5月至2010年2月，在一些医疗器械公司担任咨询。从2006年4月至2009年4月担任Photothera公司的总裁兼首席执行官。从2002年至2006年1月担任Micro Therapeutics, Inc.的总裁兼首席执行官。继2006年1月Micro Therapeutics公司和ev3 Inc.合并之后，担任ev3 Neurovascular的总裁，直到2006年4月。自1991年至2002年在Medtronic, Inc.担任各种角色。从1986年至1989年在普华永道的财务报表审计实务工作。拥有斯坦福大学的经济学文学士学位，和西北大学凯洛格管理学院的MBA学位。
Thomas C. Wilder, III has served on our board of directors since May 2010. Since August 2017 Mr. Wilder has served as Chief Executive Officer of Neuros Medical Inc., a neuromodulation company. Mr. Wilder served as the Chief Executive Officer of Sequent Medical, Inc., a company dedicated to the development of innovative catheter-based neurovascular technologies, from February 2010 to July 2016. Prior to joining Sequent Medical, Mr. Wilder served as a consultant to several medical device companies from May 2009 to February 2010. Mr. Wilder served as the President and Chief Executive Officer of Photothera, Inc. from April 2006 to April 2009. Prior to joining Photothera, Mr. Wilder served as President and Chief Executive Officer of Micro Therapeutics, Inc. from 2002 to January 2006. Mr. Wilder served as President of ev3 Neurovascular, following the merger of Micro Therapeutics, Inc. into ev3 Inc., from January 2006 to April 2006. Prior to joining Micro Therapeutics, Inc., Mr. Wilder served in positions of increasing responsibility at Medtronic, Inc. from 1991 to 2002 most recently as Vice President and General Manager of its endovascular stent grafts division. Prior to joining Medtronic, Mr. Wilder served in the Financial Statement Audit Practice of Price Waterhouse from 1986 to 1989. Mr. Wilder serves on the board of directors of Penumbra, Inc., a publicly-traded company. Mr. Wilder holds an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management and a B.A. in Economics from Stanford University. - Thomas C. Wilder, III自2010年5月起担任董事会成员。自2010年2月起担任Sequent Medical, Inc.（一家私人持有的医疗器械公司，致力于开发用于治疗神经血管性疾病的创新设备）的总裁兼首席执行官。同时，担任Benvenue Medical（一家私人拥有的医疗设备公司，专注于为快速增长的微创脊柱外科市场设计、制造和销售尖端产品）的董事。从2009年5月至2010年2月，在一些医疗器械公司担任咨询。从2006年4月至2009年4月担任Photothera公司的总裁兼首席执行官。从2002年至2006年1月担任Micro Therapeutics, Inc.的总裁兼首席执行官。继2006年1月Micro Therapeutics公司和ev3 Inc.合并之后，担任ev3 Neurovascular的总裁，直到2006年4月。自1991年至2002年在Medtronic, Inc.担任各种角色。从1986年至1989年在普华永道的财务报表审计实务工作。拥有斯坦福大学的经济学文学士学位，和西北大学凯洛格管理学院的MBA学位。
- Thomas C. Wilder, III has served on our board of directors since May 2010. Since August 2017 Mr. Wilder has served as Chief Executive Officer of Neuros Medical Inc., a neuromodulation company. Mr. Wilder served as the Chief Executive Officer of Sequent Medical, Inc., a company dedicated to the development of innovative catheter-based neurovascular technologies, from February 2010 to July 2016. Prior to joining Sequent Medical, Mr. Wilder served as a consultant to several medical device companies from May 2009 to February 2010. Mr. Wilder served as the President and Chief Executive Officer of Photothera, Inc. from April 2006 to April 2009. Prior to joining Photothera, Mr. Wilder served as President and Chief Executive Officer of Micro Therapeutics, Inc. from 2002 to January 2006. Mr. Wilder served as President of ev3 Neurovascular, following the merger of Micro Therapeutics, Inc. into ev3 Inc., from January 2006 to April 2006. Prior to joining Micro Therapeutics, Inc., Mr. Wilder served in positions of increasing responsibility at Medtronic, Inc. from 1991 to 2002 most recently as Vice President and General Manager of its endovascular stent grafts division. Prior to joining Medtronic, Mr. Wilder served in the Financial Statement Audit Practice of Price Waterhouse from 1986 to 1989. Mr. Wilder serves on the board of directors of Penumbra, Inc., a publicly-traded company. Mr. Wilder holds an M.B.A. from Northwestern University's J.L. Kellogg Graduate School of Management and a B.A. in Economics from Stanford University.
- Daniel Lemaitre
-
Daniel Lemaitre自2009年12月起担任董事。从2008年4月到2009年4月被Medtronic, Inc.（一家公开上市的医疗器械公司）收购，担任CoreValve（一家私有公司，专注于经皮主动脉瓣置换术）的总裁兼首席执行官。从2005年到2008年3月担任Medtronic的高级副总裁，领导公司的战略规划及企业发展。在加入公司之前，在医疗设备领域工作28年，担任投资分析师。包括在SG Cowen工作18年，担任董事总经理，并带领医疗保健研究团队，以及在Merrill Lynch工作6年。持有伯大尼学院的经济学文学士学位和Bowling Green州立大学的MBA学位。他也是Globus Medical, Inc.（脊柱植入物的公共持有制造商）的董事会。现任Bioventus LLC（骨愈合设备的私有开发商）的董事长，Mitralign, Inc.（心血管治疗的一家私有开发商）的董事，NDC（一家私有公司，专注于镍钛合金技术）的审计委员会主席和董事。
Daniel Lemaitre has served on our board of directors since December 2009 and has served as our Chairman since February 2017. Mr. Lemaitre served as our Lead Independent Director from March 2014 to February 2017 when our board of directors appointed him as our Chairman. Mr. Lemaitre served as President and Chief Executive Officer of Direct Flow Medical, Inc., a privately-held medical device company, from May 2015 to November 2016. Prior to joining Direct Flow Medical, Mr. Lemaitre served as Chief Executive Officer of White Pine Medical, Inc., a privately-held medical device company, from June 2009 to May 2015. Prior to White Pine Medical, Mr. Lemaitre served as the President and Chief Executive Officer of CoreValve, a privately-held company focused on percutaneous aortic valve replacement, from April 2008 until its acquisition by Medtronic, in April 2009. From 2005 to March 2008 Mr. Lemaitre was a Senior Vice President at Medtronic, where he led the company's strategic planning and corporate development. Prior to joining Medtronic, Mr. Lemaitre spent 28 years in the medical device field as an investment analyst. This included 18 years with SG Cowen, where he was a managing director and led the healthcare research team, and six years with Merrill Lynch. Mr. Lemaitre also serves on the board of directors of Globus Medical, Inc., a publicly-traded manufacturer of spinal implants. Mr. Lemaitre holds an M.B.A. from Bowling Green State University and a B.A. in Economics from Bethany College. - Daniel Lemaitre自2009年12月起担任董事。从2008年4月到2009年4月被Medtronic, Inc.（一家公开上市的医疗器械公司）收购，担任CoreValve（一家私有公司，专注于经皮主动脉瓣置换术）的总裁兼首席执行官。从2005年到2008年3月担任Medtronic的高级副总裁，领导公司的战略规划及企业发展。在加入公司之前，在医疗设备领域工作28年，担任投资分析师。包括在SG Cowen工作18年，担任董事总经理，并带领医疗保健研究团队，以及在Merrill Lynch工作6年。持有伯大尼学院的经济学文学士学位和Bowling Green州立大学的MBA学位。他也是Globus Medical, Inc.（脊柱植入物的公共持有制造商）的董事会。现任Bioventus LLC（骨愈合设备的私有开发商）的董事长，Mitralign, Inc.（心血管治疗的一家私有开发商）的董事，NDC（一家私有公司，专注于镍钛合金技术）的审计委员会主席和董事。
- Daniel Lemaitre has served on our board of directors since December 2009 and has served as our Chairman since February 2017. Mr. Lemaitre served as our Lead Independent Director from March 2014 to February 2017 when our board of directors appointed him as our Chairman. Mr. Lemaitre served as President and Chief Executive Officer of Direct Flow Medical, Inc., a privately-held medical device company, from May 2015 to November 2016. Prior to joining Direct Flow Medical, Mr. Lemaitre served as Chief Executive Officer of White Pine Medical, Inc., a privately-held medical device company, from June 2009 to May 2015. Prior to White Pine Medical, Mr. Lemaitre served as the President and Chief Executive Officer of CoreValve, a privately-held company focused on percutaneous aortic valve replacement, from April 2008 until its acquisition by Medtronic, in April 2009. From 2005 to March 2008 Mr. Lemaitre was a Senior Vice President at Medtronic, where he led the company's strategic planning and corporate development. Prior to joining Medtronic, Mr. Lemaitre spent 28 years in the medical device field as an investment analyst. This included 18 years with SG Cowen, where he was a managing director and led the healthcare research team, and six years with Merrill Lynch. Mr. Lemaitre also serves on the board of directors of Globus Medical, Inc., a publicly-traded manufacturer of spinal implants. Mr. Lemaitre holds an M.B.A. from Bowling Green State University and a B.A. in Economics from Bethany College.
- John Onopchenko
-
John Onopchenko，2007年6月再次加入本公司董事会。他是风投公司Synergy Life Science Partners, L.P.的创始人、董事总经理。2000-2006，他是Johnson & Johnson Development Corporation的风险投资副总裁；2002-2006，担任其董事。1996-1999，他担任Advanced Sterilization Products的副总裁、董事，这是Johnson & Johnson的分部。他目前是医疗和生命科学行业多个私营公司的董事。他在University of Chicago, Graduate School of Business获得商业硕士学位，在Ursinus College获得学士学位。
John Onopchenko has served on our board of directors since June 2018 and has served as our Chief Executive Officer since May 2018. He first joined us in October 2017 as our Chief Operating Officer. Prior to joining us, he served as Executive Vice President for Acutus Medical, Inc., a privately-held medical device company, from September 2016 to October 2017 where he was responsible for program management, product development, quality, marketing and sales. Prior to joining Acutus Medical, Mr. Onopchenko served as Senior Vice President and Head of Therapy Strategy for Koninklijke Philips Electronics NV, a publicly-traded technology company from March 2015 to September 2016. Prior to joining Philips, he served as Executive Vice President, from April 2013 to November 2014 and Chief Operating Officer, from November 2014 to March 2015 of Volcano Corporation, a publicly-traded medical device company, where he was responsible for its peripheral and Axsun business units, regulatory affairs, quality assurance, program management, product development, clinical affairs, and business development. Prior to his employment with Volcano, he served on Volcano's board of directors for 11 years. Mr. Onopchenko held senior positions at Johnson & Johnson, a publicly-traded medical device company, including serving as lead of medical device investments with Johnson & Johnson Development Corporation, and as Vice President of Worldwide Operations and Marketing for Advanced Sterilization Products, a Johnson & Johnson company, from 1996 to 2006. He also served as founder and managing director of Synergy Life Sciences Partners, LLC, an early-stage medical device venture capital fund. Mr. Onopchenko holds an M.B.A. from the University of Chicago, Graduate School of Business and a B.S. from Ursinus College. - John Onopchenko，2007年6月再次加入本公司董事会。他是风投公司Synergy Life Science Partners, L.P.的创始人、董事总经理。2000-2006，他是Johnson & Johnson Development Corporation的风险投资副总裁；2002-2006，担任其董事。1996-1999，他担任Advanced Sterilization Products的副总裁、董事，这是Johnson & Johnson的分部。他目前是医疗和生命科学行业多个私营公司的董事。他在University of Chicago, Graduate School of Business获得商业硕士学位，在Ursinus College获得学士学位。
- John Onopchenko has served on our board of directors since June 2018 and has served as our Chief Executive Officer since May 2018. He first joined us in October 2017 as our Chief Operating Officer. Prior to joining us, he served as Executive Vice President for Acutus Medical, Inc., a privately-held medical device company, from September 2016 to October 2017 where he was responsible for program management, product development, quality, marketing and sales. Prior to joining Acutus Medical, Mr. Onopchenko served as Senior Vice President and Head of Therapy Strategy for Koninklijke Philips Electronics NV, a publicly-traded technology company from March 2015 to September 2016. Prior to joining Philips, he served as Executive Vice President, from April 2013 to November 2014 and Chief Operating Officer, from November 2014 to March 2015 of Volcano Corporation, a publicly-traded medical device company, where he was responsible for its peripheral and Axsun business units, regulatory affairs, quality assurance, program management, product development, clinical affairs, and business development. Prior to his employment with Volcano, he served on Volcano's board of directors for 11 years. Mr. Onopchenko held senior positions at Johnson & Johnson, a publicly-traded medical device company, including serving as lead of medical device investments with Johnson & Johnson Development Corporation, and as Vice President of Worldwide Operations and Marketing for Advanced Sterilization Products, a Johnson & Johnson company, from 1996 to 2006. He also served as founder and managing director of Synergy Life Sciences Partners, LLC, an early-stage medical device venture capital fund. Mr. Onopchenko holds an M.B.A. from the University of Chicago, Graduate School of Business and a B.S. from Ursinus College.
- Guido J. Neels
-
Guido J. Neels自2010年12月起担任董事。自2006年以来一直担任Essex Woodlands Health Ventures, Inc.（一家风险投资公司）的董事总经理。之前，在Guidant公司（心血管医疗产品开发商）担任过多个管理职位。从2004年7月到2005年11退休，担任Guidant公司的首席运营官，负责Guidant公司的四个业务单元的全球业务：心脏节律管理，血管介入，心脏外科，血管内和解决方案。从2002年12月至2004年7月担任Guidant的集团董事局主席，总裁办公室，负责全球销售业务、企业传讯、企业营销、投资者关系和政府关系。2000年1月被任命为Guidant公司的总裁，负责欧洲、中东、非洲和加拿大。此外，从1996年到2000年担任Guidant公司的全球营销和血管介入副总裁，从1994年至1996年担任Guidant公司的德国和中欧总经理。从比利时的University of Leuven获得企业工程学位和斯坦福大学商业研究生院的MBA学位。从2005年至2009年担任BIOPURE公司（一家公开上市的医疗器械公司）的董事局成员，从2006年至2008年担任Lemaitre Vascular, Inc.（一家公开上市的医疗器械公司）的董事，从2006年到2010年12月被我们收购担任Nellix，Inc（私有的医疗器械公司）的董事。目前担任480 Medical, Inc., Entellus Medical, Inc., Oraya Therapeutics, Inc., Arsenal Medical, Inc., EndGenitor Technologies, Inc., Bioventus LLC， 和White Pine Medical, Inc的董事，所有都是私有医疗设备公司。根据2010年12月9日证券购买协议（经修订），被任命为Essex Woodlands Health Ventures Fund VII, L.P。（我们公司的股东，Essex Woodlands的分支机构）的董事，2010年10月27日生效。
Guido J. Neels has served as a member of our board of directors since September 2020. Mr. Neels has been with Essex Woodlands since August 2006 where he is now an Operating Partner. Prior to joining Essex Woodlands, Mr. Neels served in a variety of management positions at Guidant Corporation, a developer of cardiovascular medical products. From July 2004 until retiring in November 2005 Mr. Neels served as Guidant’s Chief Operating Officer, where he was responsible for the global operations of Guidant’s four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery and Endovascular Solutions. From December 2002 to July 2004 Mr. Neels served as Guidant’s Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. In January 2000 Mr. Neels was named Guidant’s President, Europe, Middle East, Africa and Canada. In addition, Mr. Neels served as Guidant’s Vice President, Global Marketing, Vascular Intervention, from 1996 to 2000 and as Guidant’s General Manager, Germany and Central Europe, from 1994 to 1996. Mr. Neels has served as a member of the board of managers of Bioventus LLC since May 2012. Mr. Neels also currently serves on the board of directors of Axogen, Inc. and also is a member of its compensation committee. Mr. Neels previously served on the board of directors of Endologix, Inc. from December 2010 to June 2019 and on the board of directors of Entellus Medical from November 2009 to February 2018 each of which is a public company. Mr. Neels holds a Master in Business Administration from the Stanford University Graduate School of Business and received his Business Engineering degree from the University of Leuven in Belgium. - Guido J. Neels自2010年12月起担任董事。自2006年以来一直担任Essex Woodlands Health Ventures, Inc.（一家风险投资公司）的董事总经理。之前，在Guidant公司（心血管医疗产品开发商）担任过多个管理职位。从2004年7月到2005年11退休，担任Guidant公司的首席运营官，负责Guidant公司的四个业务单元的全球业务：心脏节律管理，血管介入，心脏外科，血管内和解决方案。从2002年12月至2004年7月担任Guidant的集团董事局主席，总裁办公室，负责全球销售业务、企业传讯、企业营销、投资者关系和政府关系。2000年1月被任命为Guidant公司的总裁，负责欧洲、中东、非洲和加拿大。此外，从1996年到2000年担任Guidant公司的全球营销和血管介入副总裁，从1994年至1996年担任Guidant公司的德国和中欧总经理。从比利时的University of Leuven获得企业工程学位和斯坦福大学商业研究生院的MBA学位。从2005年至2009年担任BIOPURE公司（一家公开上市的医疗器械公司）的董事局成员，从2006年至2008年担任Lemaitre Vascular, Inc.（一家公开上市的医疗器械公司）的董事，从2006年到2010年12月被我们收购担任Nellix，Inc（私有的医疗器械公司）的董事。目前担任480 Medical, Inc., Entellus Medical, Inc., Oraya Therapeutics, Inc., Arsenal Medical, Inc., EndGenitor Technologies, Inc., Bioventus LLC， 和White Pine Medical, Inc的董事，所有都是私有医疗设备公司。根据2010年12月9日证券购买协议（经修订），被任命为Essex Woodlands Health Ventures Fund VII, L.P。（我们公司的股东，Essex Woodlands的分支机构）的董事，2010年10月27日生效。
- Guido J. Neels has served as a member of our board of directors since September 2020. Mr. Neels has been with Essex Woodlands since August 2006 where he is now an Operating Partner. Prior to joining Essex Woodlands, Mr. Neels served in a variety of management positions at Guidant Corporation, a developer of cardiovascular medical products. From July 2004 until retiring in November 2005 Mr. Neels served as Guidant’s Chief Operating Officer, where he was responsible for the global operations of Guidant’s four operating units: Cardiac Rhythm Management, Vascular Intervention, Cardiac Surgery and Endovascular Solutions. From December 2002 to July 2004 Mr. Neels served as Guidant’s Group Chairman, Office of the President, responsible for worldwide sales operations, corporate communications, corporate marketing, investor relations and government relations. In January 2000 Mr. Neels was named Guidant’s President, Europe, Middle East, Africa and Canada. In addition, Mr. Neels served as Guidant’s Vice President, Global Marketing, Vascular Intervention, from 1996 to 2000 and as Guidant’s General Manager, Germany and Central Europe, from 1994 to 1996. Mr. Neels has served as a member of the board of managers of Bioventus LLC since May 2012. Mr. Neels also currently serves on the board of directors of Axogen, Inc. and also is a member of its compensation committee. Mr. Neels previously served on the board of directors of Endologix, Inc. from December 2010 to June 2019 and on the board of directors of Entellus Medical from November 2009 to February 2018 each of which is a public company. Mr. Neels holds a Master in Business Administration from the Stanford University Graduate School of Business and received his Business Engineering degree from the University of Leuven in Belgium.
- Leslie V. Norwalk
-
Leslie V. Norwalk，2012年5月起担任董事长。2013年2月起，她还担任遵约委员会成员。她现在是Epstein Becker Green、EBG Advisors和National Health Advisors战略顾问。2008年起，她一直担任私人股权公司Warburg Pincus、Ferrer Freeman & Company和Enhanced Equity Fund顾问。2015年5月起，她担任Endologix, Inc.董事长；2014年5月起担任NuVasive, Inc.董事长；2013年起担任Adobe Healthcare和 STARUS Medical Group董事长；2012年起担任LWU Medical Faculty Associates董事长；2011年起担任Volcano Corporation董事长；2010年起担任Ika Systems Corporation董事长。她曾在George H.W.Bush政府任职，自2006年到2007年担任CMS代理管理员。她获得了Wellesley College文学士学位和George Mason University School of Law 法学博士。
Leslie V. Norwalk,Since September 2007, Ms. Norwalk has served as Strategic Counsel to Epstein Becker & Green, P.C. From 2001 to 2007, Ms. Norwalk served the Bush Administration in the Centers for Medicare & Medicaid Services (CMS). From 2006 to 2007, she was the Acting Administrator, where she managed the operations of federal health care programs, including Medicare and Medicaid. For the four years prior to that position, she was the agency's Deputy Administrator. Prior to serving the Bush Administration, Ms. Norwalk practiced law with Epstein Becker & Green, P.C. where she advised clients on a variety of healthcare policy matters. She also served the first Bush administration in the White House Office of Presidential Personnel and the Office of the U.S. Trade Representative. Ms. Norwalk is currently a director on the public company boards of NuVasive Inc., a medical device company, Neurocrine Biosciences, Inc., a biopharmaceutical company, and Arvinas Inc., a clinical-stage biopharmaceutical company. She also serves as an Advisor to several private equity funds. She received a bachelor's degree from Wellesley College and a juris doctor degree from George Mason University School of Law. - Leslie V. Norwalk，2012年5月起担任董事长。2013年2月起，她还担任遵约委员会成员。她现在是Epstein Becker Green、EBG Advisors和National Health Advisors战略顾问。2008年起，她一直担任私人股权公司Warburg Pincus、Ferrer Freeman & Company和Enhanced Equity Fund顾问。2015年5月起，她担任Endologix, Inc.董事长；2014年5月起担任NuVasive, Inc.董事长；2013年起担任Adobe Healthcare和 STARUS Medical Group董事长；2012年起担任LWU Medical Faculty Associates董事长；2011年起担任Volcano Corporation董事长；2010年起担任Ika Systems Corporation董事长。她曾在George H.W.Bush政府任职，自2006年到2007年担任CMS代理管理员。她获得了Wellesley College文学士学位和George Mason University School of Law 法学博士。
- Leslie V. Norwalk,Since September 2007, Ms. Norwalk has served as Strategic Counsel to Epstein Becker & Green, P.C. From 2001 to 2007, Ms. Norwalk served the Bush Administration in the Centers for Medicare & Medicaid Services (CMS). From 2006 to 2007, she was the Acting Administrator, where she managed the operations of federal health care programs, including Medicare and Medicaid. For the four years prior to that position, she was the agency's Deputy Administrator. Prior to serving the Bush Administration, Ms. Norwalk practiced law with Epstein Becker & Green, P.C. where she advised clients on a variety of healthcare policy matters. She also served the first Bush administration in the White House Office of Presidential Personnel and the Office of the U.S. Trade Representative. Ms. Norwalk is currently a director on the public company boards of NuVasive Inc., a medical device company, Neurocrine Biosciences, Inc., a biopharmaceutical company, and Arvinas Inc., a clinical-stage biopharmaceutical company. She also serves as an Advisor to several private equity funds. She received a bachelor's degree from Wellesley College and a juris doctor degree from George Mason University School of Law.
- Gregory D. Waller
-
Gregory D. Waller ，他是Sunshine Heart公司的董事（2011年8月以来）。他也任职Endologix Corporation（上市公司）的董事会，目前担任审计委员会主席和提名和治理委员会成员，也是Ulthera公司（一个私营公司，销售超声波设备，用于非侵入性眉部）的首席财务官。从2006年3月到2011年4月，他曾担任Universal Building Products公司（混凝土施工配件制造商）的首席财务官。他曾担任Sybron Dental Specialties公司（牙科产品消费品的制造商和销售商）的财务副总裁、首席财务官和财务主管（从1993年8月到2005年5月退休）。他也曾担任Kerr公司、Ormco Corporation、Metrex公司的副总裁兼财务主管。他于1980年12月加入Ormco Corporation，担任副总裁、总会计师。他也曾担任Kerr European公司的运营副总裁（从1989年7月到1993年8月）。他持有加州州立大学富勒顿分校（California State University, Fullerton）的工商管理硕士学位（会计）。他也曾任职几家私人公司的董事，涉及Alsius Corporation一个上市公司，担任审计委员会主席和薪酬委员会的成员（从2007年6月到2009年9月被Zoll Medical Corporation收购）、 Biolase Technology公司（一家上市公司，担任审计委员会的主席）（从2009年10月到2010年8月）、 Cardiogenesis Corporation（公开交易的公司，公开交易的公司）、（从2007年4月到2011年5月被Cryolife公司收购）、Clarient公司（上市公司，于2010年12月被General Electric Company收购，担任审计委员会主席、薪酬和公司治理委员会的成员）（从2006年12月到2010年12月），SenoRx公司（一个于2010年7月被C.R.Bard公司收购的上市公司，担任审计委员会主席）（从2006年5月到2010年7月）。
Gregory D. Waller has served as a director of the Company since June 2017. He has also served as a board member of Nullis, Inc. since Augt 2011, a publicly traded company. From October 2011 to October 2015, Mr. Waller was Chief Financial Officer of Ulthera Corporation, a privately held company providing ultrasound technology for aesthetic and medical applications, which was sold to Merz North America in July 2014. From March 2006 until April 2011, Mr. Waller was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories. Mr. Waller served as Vice President Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from Augt 1993 until his retirement in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller's prior board experience includes service as a director for the following publicly-traded companies: Endologix Corporation, from November 2003 to October 2020; Cardiogenesis Corporation, from April 2007 until its acquisition by Cryolife in 2011; Clarient, Inc., from December 2006 until its acquisition by General Electric Company in December 2010; Biolase Technology, Inc., from October 2009 to August 2010; SenoRx, Inc., from May 2006 until its acquisition by C.R. Bard, Inc. in July 2010; and Alsius Corporation, from June 2007 until its acquisition by Zoll Medical Corporation in September 2009. Mr. Waller has a Master of Business Administration with a concentration in accounting from California State University, Fullerton. - Gregory D. Waller ，他是Sunshine Heart公司的董事（2011年8月以来）。他也任职Endologix Corporation（上市公司）的董事会，目前担任审计委员会主席和提名和治理委员会成员，也是Ulthera公司（一个私营公司，销售超声波设备，用于非侵入性眉部）的首席财务官。从2006年3月到2011年4月，他曾担任Universal Building Products公司（混凝土施工配件制造商）的首席财务官。他曾担任Sybron Dental Specialties公司（牙科产品消费品的制造商和销售商）的财务副总裁、首席财务官和财务主管（从1993年8月到2005年5月退休）。他也曾担任Kerr公司、Ormco Corporation、Metrex公司的副总裁兼财务主管。他于1980年12月加入Ormco Corporation，担任副总裁、总会计师。他也曾担任Kerr European公司的运营副总裁（从1989年7月到1993年8月）。他持有加州州立大学富勒顿分校（California State University, Fullerton）的工商管理硕士学位（会计）。他也曾任职几家私人公司的董事，涉及Alsius Corporation一个上市公司，担任审计委员会主席和薪酬委员会的成员（从2007年6月到2009年9月被Zoll Medical Corporation收购）、 Biolase Technology公司（一家上市公司，担任审计委员会的主席）（从2009年10月到2010年8月）、 Cardiogenesis Corporation（公开交易的公司，公开交易的公司）、（从2007年4月到2011年5月被Cryolife公司收购）、Clarient公司（上市公司，于2010年12月被General Electric Company收购，担任审计委员会主席、薪酬和公司治理委员会的成员）（从2006年12月到2010年12月），SenoRx公司（一个于2010年7月被C.R.Bard公司收购的上市公司，担任审计委员会主席）（从2006年5月到2010年7月）。
- Gregory D. Waller has served as a director of the Company since June 2017. He has also served as a board member of Nullis, Inc. since Augt 2011, a publicly traded company. From October 2011 to October 2015, Mr. Waller was Chief Financial Officer of Ulthera Corporation, a privately held company providing ultrasound technology for aesthetic and medical applications, which was sold to Merz North America in July 2014. From March 2006 until April 2011, Mr. Waller was Chief Financial Officer of Universal Building Products, a manufacturer of concrete construction accessories. Mr. Waller served as Vice President Finance, Chief Financial Officer and Treasurer of Sybron Dental Specialties, Inc., a manufacturer and marketer of consumable dental products, from Augt 1993 until his retirement in May 2005 and was formerly the Vice President and Treasurer of Kerr, Ormco Corporation, and Metrex. Mr. Waller's prior board experience includes service as a director for the following publicly-traded companies: Endologix Corporation, from November 2003 to October 2020; Cardiogenesis Corporation, from April 2007 until its acquisition by Cryolife in 2011; Clarient, Inc., from December 2006 until its acquisition by General Electric Company in December 2010; Biolase Technology, Inc., from October 2009 to August 2010; SenoRx, Inc., from May 2006 until its acquisition by C.R. Bard, Inc. in July 2010; and Alsius Corporation, from June 2007 until its acquisition by Zoll Medical Corporation in September 2009. Mr. Waller has a Master of Business Administration with a concentration in accounting from California State University, Fullerton.
- Thomas F. Zenty, III
-
Thomas F. Zenty, III自2013年5月起担任董事。目前担任美国俄亥俄州克里夫兰市University Hospitals Health System的总裁兼首席执行官。此前，曾在Cedars-Sinai Health System, St. Joseph’s Medical Center, Catholic Health Care West的一个部门， Franciscan Health System of New Jersey和St. Mary Hospital, Connecticut担任多个高管职位。担任Western Reserve Assurance Company, Ltd. SPC（一家私人持有的保险公司）的董事长，并担任The Coalition to Protect America's Health Care的主席。他是美国医院协会的前任董事会成员，还担任过全国金融服务董事会董事。曾在众多有名望的大学担任多个学术职务，包括当前担任Case Western Reserve University的银行和金融学兼职教授。他从纽约大学获得公共管理硕士学位，从泽维尔大学获得医院管理硕士学位，以及宾夕法尼亚州立大学的卫生规划学士学位。
Thomas F. Zenty, III has served on our board of directors since May 2013. Mr. Zenty currently serves as the President and Chief Executive Officer of University Hospitals Health System, Inc., Cleveland, Ohio. Mr. Zenty held various executive positions with Cedars-Sinai Health System, St. Joseph's Medical Center, a division of Dignity Health, Franciscan Health System of New Jersey and St. Mary Hospital, Connecticut from 1980 to 2003. Mr. Zenty is Chairman of the Board of Western Reserve Assurance Company, Ltd. SPC, a privately-held insurance company. Mr. Zenty previously served on the boards of directors of the American Hospital Association and Nationwide Financial Services, Inc., both privately-held companies. Mr. Zenty has held several academic positions with prestigious universities, including his current position as Adjunct Professor, Banking & Finance at Case Western Reserve University, and chaired The Coalition to Protect America's Health Care. Mr. Zenty holds an M.P.A. in Public Administration from New York University, a M.H.S.A. in Hospital Administration from Xavier University, and a B.A. in Health Planning from Pennsylvania State University. - Thomas F. Zenty, III自2013年5月起担任董事。目前担任美国俄亥俄州克里夫兰市University Hospitals Health System的总裁兼首席执行官。此前，曾在Cedars-Sinai Health System, St. Joseph’s Medical Center, Catholic Health Care West的一个部门， Franciscan Health System of New Jersey和St. Mary Hospital, Connecticut担任多个高管职位。担任Western Reserve Assurance Company, Ltd. SPC（一家私人持有的保险公司）的董事长，并担任The Coalition to Protect America's Health Care的主席。他是美国医院协会的前任董事会成员，还担任过全国金融服务董事会董事。曾在众多有名望的大学担任多个学术职务，包括当前担任Case Western Reserve University的银行和金融学兼职教授。他从纽约大学获得公共管理硕士学位，从泽维尔大学获得医院管理硕士学位，以及宾夕法尼亚州立大学的卫生规划学士学位。
- Thomas F. Zenty, III has served on our board of directors since May 2013. Mr. Zenty currently serves as the President and Chief Executive Officer of University Hospitals Health System, Inc., Cleveland, Ohio. Mr. Zenty held various executive positions with Cedars-Sinai Health System, St. Joseph's Medical Center, a division of Dignity Health, Franciscan Health System of New Jersey and St. Mary Hospital, Connecticut from 1980 to 2003. Mr. Zenty is Chairman of the Board of Western Reserve Assurance Company, Ltd. SPC, a privately-held insurance company. Mr. Zenty previously served on the boards of directors of the American Hospital Association and Nationwide Financial Services, Inc., both privately-held companies. Mr. Zenty has held several academic positions with prestigious universities, including his current position as Adjunct Professor, Banking & Finance at Case Western Reserve University, and chaired The Coalition to Protect America's Health Care. Mr. Zenty holds an M.P.A. in Public Administration from New York University, a M.H.S.A. in Hospital Administration from Xavier University, and a B.A. in Health Planning from Pennsylvania State University.
高管简历
中英对照 | 中文 | 英文- Vaseem Mahboob
Vaseem Mahboob是首席财务官。他自2021年起担任Kestra Medical Technologies， Ltd.的这一职务。Mahboob先生拥有超过23年的财务领导经验。在加入公司之前，Mahboob先生从2020年到2021年担任DIH Technology Ltd.的执行副总裁、首席财务官和首席运营官。2015年至2020年，Mahboob先生担任ENDOLOGIX Inc.的首席财务官。ENDOLOGIX公司于2020年7月向美国德克萨斯州北区破产法院申请了第11章破产保护。Mahboob先生也是INSYS Therapeutics的董事会成员和审计委员会主席（2018年至2019年）。在ENDOLOGIX Inc.之前，Mahboob先生在GE Healthcare担任多个职位，包括2006年至2010年担任全球磁共振业务首席财务官，2010年至2012年担任全球超声业务首席财务官，2013年至2015年担任东部和非洲增长市场首席财务官，2015年6月至2015年9月担任GE Healthcare IT首席财务官。他持有纽约州立大学雅各布斯管理学院的金融市场、机构和信息系统工商管理硕士学位。
Vaseem Mahboob,has served in this role at Kestra Medical Technologies, Ltd. since 2021. Mr. Mahboob has over 23 years of finance leadership experience. Prior to joining Kestra Medical Technologies, Ltd. company, Mr. Mahboob served as the Executive Vice President, Chief Financial Officer and Chief Operations Officer of DIH Technology Ltd. from 2020 to 2021. From 2015 to 2020, Mr. Mahboob served as the Chief Financial Officer of ENDOLOGIX Inc. ENDOLOGIX Inc. filed for Chapter 11 bankruptcy protection with the United States Bankruptcy Court for the Northern District of Texas in July 2020. Mr. Mahboob was also a member of the board of directors and the audit committee chair for INSYS Therapeutics from 2018 to 2019. Prior to ENDOLOGIX Inc., Mr. Mahboob held various positions at GE Healthcare, including as the Chief Financial Officer of the Global Magnetic Resonance Business from 2006 to 2010, as Chief Financial Officer of the Global Ultrasound Business from 2010 to 2012, as Chief Financial Officer of the Eastern and African Growth Markets from 2013 to 2015 and as Chief Financial Officer of GE Healthcare IT from June 2015 to September 2015. Mr. Mahboob received his M.B.A. in Financial Markets and Institutions and Information Systems from the Jacobs School of Management at the State University of New York.- Vaseem Mahboob是首席财务官。他自2021年起担任Kestra Medical Technologies， Ltd.的这一职务。Mahboob先生拥有超过23年的财务领导经验。在加入公司之前，Mahboob先生从2020年到2021年担任DIH Technology Ltd.的执行副总裁、首席财务官和首席运营官。2015年至2020年，Mahboob先生担任ENDOLOGIX Inc.的首席财务官。ENDOLOGIX公司于2020年7月向美国德克萨斯州北区破产法院申请了第11章破产保护。Mahboob先生也是INSYS Therapeutics的董事会成员和审计委员会主席（2018年至2019年）。在ENDOLOGIX Inc.之前，Mahboob先生在GE Healthcare担任多个职位，包括2006年至2010年担任全球磁共振业务首席财务官，2010年至2012年担任全球超声业务首席财务官，2013年至2015年担任东部和非洲增长市场首席财务官，2015年6月至2015年9月担任GE Healthcare IT首席财务官。他持有纽约州立大学雅各布斯管理学院的金融市场、机构和信息系统工商管理硕士学位。
- Vaseem Mahboob,has served in this role at Kestra Medical Technologies, Ltd. since 2021. Mr. Mahboob has over 23 years of finance leadership experience. Prior to joining Kestra Medical Technologies, Ltd. company, Mr. Mahboob served as the Executive Vice President, Chief Financial Officer and Chief Operations Officer of DIH Technology Ltd. from 2020 to 2021. From 2015 to 2020, Mr. Mahboob served as the Chief Financial Officer of ENDOLOGIX Inc. ENDOLOGIX Inc. filed for Chapter 11 bankruptcy protection with the United States Bankruptcy Court for the Northern District of Texas in July 2020. Mr. Mahboob was also a member of the board of directors and the audit committee chair for INSYS Therapeutics from 2018 to 2019. Prior to ENDOLOGIX Inc., Mr. Mahboob held various positions at GE Healthcare, including as the Chief Financial Officer of the Global Magnetic Resonance Business from 2006 to 2010, as Chief Financial Officer of the Global Ultrasound Business from 2010 to 2012, as Chief Financial Officer of the Eastern and African Growth Markets from 2013 to 2015 and as Chief Financial Officer of GE Healthcare IT from June 2015 to September 2015. Mr. Mahboob received his M.B.A. in Financial Markets and Institutions and Information Systems from the Jacobs School of Management at the State University of New York.
- Jeremy Hayden
Jeremy Hayden于2017年8月加入我们，并担任我们的总法律顾问兼公司秘书。加入我们之前，他曾担任Cytori Therapeutics，Inc.的总法律顾问，在那里他负责所有全球法律、合规和知识产权活动。在加入Cytori之前，海登曾在Volcano Corporation担任助理总法律顾问，在那里，他为Volcano的许多关键部门提供支持，直接负责SEC的所有备案、广告和促销审查，并负责亚洲和欧洲的国际法律事务，包括分销协议，合作伙伴关系和合规性。在加入Volcano之前，Hayden先生是几家国际律师事务所的公司和证券律师，包括Brobeck，Phleger&Harrison LLP，Sheppard Mullin Richter&Hampton LLP和McKenna Long&Aldridge LLP，在那里他为医疗设备公司提供风险投资的法律顾问，股权和债务融资，合伙企业和公司法律事项。Hayden先生拥有密歇根大学法学院（University of Michigan Law School）法学博士学位和普林斯顿大学（Princeton University）政治学学士学位。
Jeremy Hayden,served as General Counsel of Endologix, Inc., a medical device company focused on vascular disease. Prior to that, Mr. Hayden served as General Counsel and Vice President, Business Development at Cytori Therapeutics, Inc., a life sciences company (now Plus Therapeutics, Nasdaq CM: PSTV) from July 2015 to August 2017, and from May 2012 to July 2015, he served as Assistant General Counsel at Volcano Corporation, a publicly traded medical device company that was acquired by Royal Phillips in 2015. Mr. Hayden holds a J.D. from the University of Michigan Law School and an A.B. in Politics from Princeton University.- Jeremy Hayden于2017年8月加入我们，并担任我们的总法律顾问兼公司秘书。加入我们之前，他曾担任Cytori Therapeutics，Inc.的总法律顾问，在那里他负责所有全球法律、合规和知识产权活动。在加入Cytori之前，海登曾在Volcano Corporation担任助理总法律顾问，在那里，他为Volcano的许多关键部门提供支持，直接负责SEC的所有备案、广告和促销审查，并负责亚洲和欧洲的国际法律事务，包括分销协议，合作伙伴关系和合规性。在加入Volcano之前，Hayden先生是几家国际律师事务所的公司和证券律师，包括Brobeck，Phleger&Harrison LLP，Sheppard Mullin Richter&Hampton LLP和McKenna Long&Aldridge LLP，在那里他为医疗设备公司提供风险投资的法律顾问，股权和债务融资，合伙企业和公司法律事项。Hayden先生拥有密歇根大学法学院（University of Michigan Law School）法学博士学位和普林斯顿大学（Princeton University）政治学学士学位。
- Jeremy Hayden,served as General Counsel of Endologix, Inc., a medical device company focused on vascular disease. Prior to that, Mr. Hayden served as General Counsel and Vice President, Business Development at Cytori Therapeutics, Inc., a life sciences company (now Plus Therapeutics, Nasdaq CM: PSTV) from July 2015 to August 2017, and from May 2012 to July 2015, he served as Assistant General Counsel at Volcano Corporation, a publicly traded medical device company that was acquired by Royal Phillips in 2015. Mr. Hayden holds a J.D. from the University of Michigan Law School and an A.B. in Politics from Princeton University.
- Matthew Thompson
Matthew Thompson于2020年6月加入我们的董事会。自2016年12月以来，Thompson博士一直担任Endologix LLC的首席医疗官。Thompson博士自2017年起担任斯坦福大学医学院的兼职教授，自2020年起担任凯斯西储大学克利夫兰诊所勒纳医学院的合同外科医生和客座教授。加入Endologix公司之前，Thompson博士曾担任St.George’s University of London和St.George’s Vascular Institute的血管外科教授（2002年至2016年）。Thompson博士的奖项包括Hunterian教授职位，Moynihan Traveling Fellowship和校际考试金牌。Thompson博士也是牛津血管外科教科书和牛津血管外科手册的编辑。Thompson博士曾担任血管服务国家专业委托临床参考小组主席（2013年至2016年），并且是英国血管内治疗学会的创始人-2004年Thompson博士曾担任血管学会理事会成员（2014年至2017年），以及血管学会年度科学会议主席（2014年至2017年）。Thompson博士曾担任三个全伦敦服务重组（心血管疾病、重大创伤和紧急服务）的临床总监（2010年至2013年）。Thompson博士在剑桥大学（1981-1984）、圣巴塞洛缪医院（1984-1987）、莱斯特大学（1994）和阿德莱德大学（1998）接受培训。
Matthew Thompson joined board of directors in June 2020. In 2025, Dr. Thompson became the Executive Vice President and Chief Medical Officer of Endologix LLC. In March 2025, Dr. Thompson became the Chief Executive Officer and in 2024, he became a Director of Life Seal Vascular. Prior to January 2025 and since 2021, he was the President and Chief Executive Officer (CEO) of Endologix LLC]. Previo to his tenure with Endologix LLC, Dr. Thompson was the Professor of Vascular Surgery at St George's, University of London and Staff Surgeon in the Department of Vascular Surgery at the Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Ohio. Dr. Thompson trained at Cambridge, St Bartholomew's Hospital, the University of Leicester and Adelaide. He studied corporate innovation at Stanford University, Graduate School of Biness. His awards include a Hunterian Professorship, the Moynihan travelling fellowship and the gold medal for the intercollegiate examination. His named lectures include the Kinmonth Lecture (Vascular Society Great Britain and Ireland), the British Jnal of Surgery Lecture (Vascular Society Great Britain and Ireland), and the Chee Song Memorial Lecture (British Society of Endovascular Therapy). He has published over 400 peer revied articles. His clinical interests re in the treatment of aortic disease and endovascular surgery. His research interests include health service outcome research, clinical trials, and translational investigations into aortic disease. Dr. Thompson is the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery. He has been the clinical director for three London wide service reconfigurations (cardiovascular disease, major trauma, and emergency services). He was Chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services. He is a founder of the British Society for Endovascular Therapy, a past Council Member of the Vascular Society, was Chairman of the Vascular Society Annual Scientific Meeting and was awarded a Lifetime Achievement Award by the Vascular Society of Great Britain and Ireland in 2017.- Matthew Thompson于2020年6月加入我们的董事会。自2016年12月以来，Thompson博士一直担任Endologix LLC的首席医疗官。Thompson博士自2017年起担任斯坦福大学医学院的兼职教授，自2020年起担任凯斯西储大学克利夫兰诊所勒纳医学院的合同外科医生和客座教授。加入Endologix公司之前，Thompson博士曾担任St.George’s University of London和St.George’s Vascular Institute的血管外科教授（2002年至2016年）。Thompson博士的奖项包括Hunterian教授职位，Moynihan Traveling Fellowship和校际考试金牌。Thompson博士也是牛津血管外科教科书和牛津血管外科手册的编辑。Thompson博士曾担任血管服务国家专业委托临床参考小组主席（2013年至2016年），并且是英国血管内治疗学会的创始人-2004年Thompson博士曾担任血管学会理事会成员（2014年至2017年），以及血管学会年度科学会议主席（2014年至2017年）。Thompson博士曾担任三个全伦敦服务重组（心血管疾病、重大创伤和紧急服务）的临床总监（2010年至2013年）。Thompson博士在剑桥大学（1981-1984）、圣巴塞洛缪医院（1984-1987）、莱斯特大学（1994）和阿德莱德大学（1998）接受培训。
- Matthew Thompson joined board of directors in June 2020. In 2025, Dr. Thompson became the Executive Vice President and Chief Medical Officer of Endologix LLC. In March 2025, Dr. Thompson became the Chief Executive Officer and in 2024, he became a Director of Life Seal Vascular. Prior to January 2025 and since 2021, he was the President and Chief Executive Officer (CEO) of Endologix LLC]. Previo to his tenure with Endologix LLC, Dr. Thompson was the Professor of Vascular Surgery at St George's, University of London and Staff Surgeon in the Department of Vascular Surgery at the Heart, Vascular and Thoracic Institute, Cleveland Clinic Foundation, Ohio. Dr. Thompson trained at Cambridge, St Bartholomew's Hospital, the University of Leicester and Adelaide. He studied corporate innovation at Stanford University, Graduate School of Biness. His awards include a Hunterian Professorship, the Moynihan travelling fellowship and the gold medal for the intercollegiate examination. His named lectures include the Kinmonth Lecture (Vascular Society Great Britain and Ireland), the British Jnal of Surgery Lecture (Vascular Society Great Britain and Ireland), and the Chee Song Memorial Lecture (British Society of Endovascular Therapy). He has published over 400 peer revied articles. His clinical interests re in the treatment of aortic disease and endovascular surgery. His research interests include health service outcome research, clinical trials, and translational investigations into aortic disease. Dr. Thompson is the editor of the Oxford Textbook of Vascular Surgery and the Oxford Handbook of Vascular Surgery. He has been the clinical director for three London wide service reconfigurations (cardiovascular disease, major trauma, and emergency services). He was Chair of the National Specialized Commissioning Clinical Reference Group for Vascular Services. He is a founder of the British Society for Endovascular Therapy, a past Council Member of the Vascular Society, was Chairman of the Vascular Society Annual Scientific Meeting and was awarded a Lifetime Achievement Award by the Vascular Society of Great Britain and Ireland in 2017.
- John Onopchenko
John Onopchenko，2007年6月再次加入本公司董事会。他是风投公司Synergy Life Science Partners, L.P.的创始人、董事总经理。2000-2006，他是Johnson & Johnson Development Corporation的风险投资副总裁；2002-2006，担任其董事。1996-1999，他担任Advanced Sterilization Products的副总裁、董事，这是Johnson & Johnson的分部。他目前是医疗和生命科学行业多个私营公司的董事。他在University of Chicago, Graduate School of Business获得商业硕士学位，在Ursinus College获得学士学位。
John Onopchenko has served on our board of directors since June 2018 and has served as our Chief Executive Officer since May 2018. He first joined us in October 2017 as our Chief Operating Officer. Prior to joining us, he served as Executive Vice President for Acutus Medical, Inc., a privately-held medical device company, from September 2016 to October 2017 where he was responsible for program management, product development, quality, marketing and sales. Prior to joining Acutus Medical, Mr. Onopchenko served as Senior Vice President and Head of Therapy Strategy for Koninklijke Philips Electronics NV, a publicly-traded technology company from March 2015 to September 2016. Prior to joining Philips, he served as Executive Vice President, from April 2013 to November 2014 and Chief Operating Officer, from November 2014 to March 2015 of Volcano Corporation, a publicly-traded medical device company, where he was responsible for its peripheral and Axsun business units, regulatory affairs, quality assurance, program management, product development, clinical affairs, and business development. Prior to his employment with Volcano, he served on Volcano's board of directors for 11 years. Mr. Onopchenko held senior positions at Johnson & Johnson, a publicly-traded medical device company, including serving as lead of medical device investments with Johnson & Johnson Development Corporation, and as Vice President of Worldwide Operations and Marketing for Advanced Sterilization Products, a Johnson & Johnson company, from 1996 to 2006. He also served as founder and managing director of Synergy Life Sciences Partners, LLC, an early-stage medical device venture capital fund. Mr. Onopchenko holds an M.B.A. from the University of Chicago, Graduate School of Business and a B.S. from Ursinus College.- John Onopchenko，2007年6月再次加入本公司董事会。他是风投公司Synergy Life Science Partners, L.P.的创始人、董事总经理。2000-2006，他是Johnson & Johnson Development Corporation的风险投资副总裁；2002-2006，担任其董事。1996-1999，他担任Advanced Sterilization Products的副总裁、董事，这是Johnson & Johnson的分部。他目前是医疗和生命科学行业多个私营公司的董事。他在University of Chicago, Graduate School of Business获得商业硕士学位，在Ursinus College获得学士学位。
- John Onopchenko has served on our board of directors since June 2018 and has served as our Chief Executive Officer since May 2018. He first joined us in October 2017 as our Chief Operating Officer. Prior to joining us, he served as Executive Vice President for Acutus Medical, Inc., a privately-held medical device company, from September 2016 to October 2017 where he was responsible for program management, product development, quality, marketing and sales. Prior to joining Acutus Medical, Mr. Onopchenko served as Senior Vice President and Head of Therapy Strategy for Koninklijke Philips Electronics NV, a publicly-traded technology company from March 2015 to September 2016. Prior to joining Philips, he served as Executive Vice President, from April 2013 to November 2014 and Chief Operating Officer, from November 2014 to March 2015 of Volcano Corporation, a publicly-traded medical device company, where he was responsible for its peripheral and Axsun business units, regulatory affairs, quality assurance, program management, product development, clinical affairs, and business development. Prior to his employment with Volcano, he served on Volcano's board of directors for 11 years. Mr. Onopchenko held senior positions at Johnson & Johnson, a publicly-traded medical device company, including serving as lead of medical device investments with Johnson & Johnson Development Corporation, and as Vice President of Worldwide Operations and Marketing for Advanced Sterilization Products, a Johnson & Johnson company, from 1996 to 2006. He also served as founder and managing director of Synergy Life Sciences Partners, LLC, an early-stage medical device venture capital fund. Mr. Onopchenko holds an M.B.A. from the University of Chicago, Graduate School of Business and a B.S. from Ursinus College.